Wednesday, April 2, 2025
Home Authors Posts by Editor / Curator

Editor / Curator

934 POSTS 0 COMMENTS
Compass Pathways, Biotech Stock Review
IPOS

Magic Mushroom Compass Pathways (CMPS) IPO Valued at Near $1 Billion.

Editor / Curator -
Stand Down.

Fed President, Neel Kashkari: Ending Privatized Profits and Socialized Losses.

Editor / Curator -
Biotech Stocks
Telehealth

Telehealth: How the Pandemic Forced Mental Health Care to Change for...

Editor / Curator -
Sorrento Theraputics, Biotech STock Review
Superbug News - CoronaVirus Watch List

Adding Sorrento Therapeutics (SRNE) to CoronaVirus Watch List.

Editor / Curator -
IPOS

Snowflake (SNOW) vs Facebook (FB) IPO.

Editor / Curator -
Telehealth

Mitesco Inc. Initiates “The Good Clinic” Rollout in Minneapolis; Introduces the...

Editor / Curator -
aPHEX bIOcLEANSE
Superbug News - CoronaVirus Watch List

Hy-IQ Trademark

Editor / Curator -
Biotech News

Aphex BioCleanse Systems (APHX) Plans Filing With Securities & Exchange Commission.

Editor / Curator -
2020 Watch List

Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea...

Editor / Curator -
American BriVision
Biotech News

American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.

Editor / Curator -
1...616263...94Page 62 of 94

Latest article

Bavarian Nordic (BVNRY) Freeze Dries its MPOX Vaccine!

2025 Watch List Editor / Curator -
This is Big News, Honestly. We Are Adding to 2025 Watch List @ $7.36. We last added Bavarian to...

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.’s ‘Misinformation And Lies’ (IBD)

All News Editor / Curator -
Sorting Through the Wreckage! Full post on Investor's Business Daily. Biotech stocks took a beating Monday...

Zomedica (ZOMDF) Surges 40% Higher, Friday.

All News Editor / Curator -
Stock Surges 40%, After Management Conference Call to Calm the Natives. Insider Buying Unleashed Today? Not...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.